Head-to-head · WeighScore
CoreAge Rx vs MyDrHank
By GLP-1 ScorecardUpdated
Score comparison
CoreAge Rx has the higher recorded score — 89.5/100 to 68.2/100.
CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
CoreAge Rx scores 89.5/100 (B+).
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | CoreAge Rx | MyDrHank |
|---|---|---|
| WeighScore | 89.5/100 | 68.2/100 |
| Grade | B+ | C |
| Site position | #1 | #105 |
| Semaglutide | Product page from $79/mo; navigation $99. Confirm selected quote. | From $171/mo oral or injectable on GLP-1 lander; injection product page from $178/mo (conflicting offer terms; confirm) |
| Tirzepatide | From $129/mo advertised; confirm selected charge, supply and renewal. | From $200/mo on GLP-1 lander; product page from $240/mo (conflicting offer terms; confirm) |
| Coverage | US only; therapy-specific state restrictions apply | Confirm prescription and state; contiguous-U.S. shipping claim does not establish individual eligibility |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Yes |
Site position #1 · B+
Strengths
- Current product pages advertise starting prices of $79 for semaglutide and $129 for tirzepatide
- Advertises the same price across doses and no membership fee
- Publishes cancellation, fulfillment and refund rules and a way to request the assigned pharmacy
What to consider
- Starting prices vary across public displays and do not establish a selected invoice or usable prescription supply
- FAQ no-rebill and payment-timing statements differ from the subscription and order policy
- FAQ promises a full rejection refund, while policy retains an applicable $50–$100 consultation fee after review begins
- Refund policy makes orders final after approval and pharmacy transmission; Terms also refer to review completion/transmission with policy exceptions. Confirm the cutoff and separate thirty-day documentation limit.
- Actual clinician, dispenser, physical compounder, lab cost and treatment-state eligibility need confirmation
Site position #105 · C
Strengths
- Public landing and product pages show starting prices before medical intake
- Compounded injection options and a separate oral semaglutide menu are advertised, with formulation differences to discuss with the prescriber
- Product pages advertise consultation, delivery, check-ins and unlimited clinical messaging; response times were not tested
- Terms identify the platform operator and offer the current pharmacy-partner list on request
What to consider
- The GLP-1 lander shows $171/$200 injectable starting rates, while separate injection pages show $178/$240; applicable purchase terms remain unresolved
- Published base plan fields do not establish that a particular promotion is unavailable or what an individual will actually pay
- The reviewed GLP-1 terms did not establish the cancellation cutoff, unused-prepayment refund formula or declined-treatment financial outcome
- The assigned medical practice, prescriber and dispensing location remain unestablished; no current individual license verification is claimed
- Dose, concentration, usable supply, laboratory costs and state-specific availability require confirmation
- Compounded preparations are not FDA-approved; displayed branded-product trial results do not establish outcomes for these formulations
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.